Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Namrata Saroj Sells 35,370 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Namrata Saroj sold 35,370 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $6.55, for a total value of $231,673.50. Following the completion of the sale, the insider owned 220,522 shares in the company, valued at $1,444,419.10. This represents a 13.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Performance

OCUL opened at $6.61 on Wednesday. Ocular Therapeutix, Inc. has a 12-month low of $6.00 and a 12-month high of $16.44. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -4.53 and a beta of 1.22. The business has a 50 day moving average of $8.25 and a 200-day moving average of $8.97. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 56.26% and a negative net margin of 648.64%. The business had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.27 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The firm’s revenue was down 11.5% compared to the same quarter last year. On average, equities research analysts expect that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current year.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

  • Positive Sentiment: Ocular Therapeutix plans to submit its AXPAXLI NDA in the fourth quarter of 2026 and reported $530.6 million in cash, which it expects to support operations into 2028. The filing target supports the pipeline outlook, while the cash balance reduces near-term financing concerns. Article: AXPAXLI NDA plan and cash runway
  • Positive Sentiment: HC Wainwright raised its price target to $28 from $25 and maintained a Buy rating, signaling confidence in the company’s prospects despite recent operating results. Analyst rating information
  • Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated purpose makes the transaction less indicative of a discretionary view on OCUL. SEC insider transaction filing
  • Negative Sentiment: Third-quarter results missed expectations: the loss was $0.42 per share versus the expected $0.36 loss, while revenue of $12.87 million fell short of the $14.27 million consensus and declined 11.5% year over year. These results weighed on sentiment. Article: Ocular Therapeutix falls on third-quarter earnings miss
  • Negative Sentiment: Reports also pointed to costs from advancing AXPAXLI and declining DEXTENZA sales, highlighting near-term operating challenges even as the company pursues its pipeline. Article: Q3 results, pipeline costs, and DEXTENZA

Wall Street Analysts Forecast Growth

Several equities analysts have commented on OCUL shares. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. UBS Group assumed coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They issued a “buy” rating and a $14.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $23.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Monday, October 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.83.

Check Out Our Latest Analysis on OCUL

Hedge Funds Weigh In On Ocular Therapeutix

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Ocular Therapeutix during the 2nd quarter worth approximately $190,278,000. Commodore Capital LP acquired a new position in Ocular Therapeutix in the 1st quarter valued at $21,810,000. Readystate Asset Management LP acquired a new position in Ocular Therapeutix in the 1st quarter valued at $7,484,000. Defilade Capital Management L.P. grew its holdings in Ocular Therapeutix by 118.2% in the 1st quarter. Defilade Capital Management L.P. now owns 1,487,645 shares of the biopharmaceutical company’s stock valued at $12,600,000 after buying an additional 805,982 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Ocular Therapeutix during the 1st quarter worth $5,491,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

Recommended Stories

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.